Wave Life Sciences Pte. Ltd. (NASDAQ:WVE)‘s stock had its “outperform” rating reissued by Leerink Swann in a research report issued on Thursday. They presently have a $45.00 price target on the stock. Leerink Swann’s target price suggests a potential upside of 23.29% from the stock’s previous close.

Other analysts have also issued reports about the stock. Jefferies Group set a $28.00 price target on shares of Wave Life Sciences Pte. and gave the stock a “buy” rating in a research report on Monday, August 15th. JMP Securities reaffirmed a “buy” rating on shares of Wave Life Sciences Pte. in a research report on Tuesday, August 16th. Finally, Zacks Investment Research raised shares of Wave Life Sciences Pte. from a “sell” rating to a “hold” rating in a research report on Wednesday, October 19th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $30.80.

Wave Life Sciences Pte. (NASDAQ:WVE) opened at 36.50 on Thursday. The firm has a 50-day moving average of $31.75 and a 200-day moving average of $22.92. Wave Life Sciences Pte. has a 52-week low of $8.95 and a 52-week high of $38.50. The firm’s market capitalization is $855.56 million.

Wave Life Sciences Pte. (NASDAQ:WVE) last posted its quarterly earnings results on Monday, August 15th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.14. On average, equities research analysts forecast that Wave Life Sciences Pte. will post ($2.17) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of WVE. Wells Fargo & Company MN bought a new position in shares of Wave Life Sciences Pte. during the third quarter valued at $136,000. BlackRock Advisors LLC raised its position in Wave Life Sciences Pte. by 67.6% in the third quarter. BlackRock Advisors LLC now owns 4,264 shares of the company’s stock worth $138,000 after buying an additional 1,720 shares in the last quarter. Strs Ohio acquired a new position in Wave Life Sciences Pte. during the third quarter worth approximately $194,000. Lesa Sroufe & Co acquired a new position in Wave Life Sciences Pte. during the third quarter worth approximately $209,000. Finally, Teachers Advisors Inc. acquired a new position in Wave Life Sciences Pte. during the second quarter worth approximately $246,000. 61.15% of the stock is currently owned by institutional investors.

About Wave Life Sciences Pte.

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Receive News & Stock Ratings for Wave Life Sciences Pte. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Pte. Ltd. and related stocks with our FREE daily email newsletter.